Evidence map›Paper›PMID 21387272›Full record

ArticleCancer2011

How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?

Janneke A Wilschut, Ewout W Steyerberg, Monique E van Leerdam, Iris Lansdorp-Vogelaar, J Dik F Habbema, Marjolein van Ballegooijen

Open access · greenAbstract read
In one paragraph

Article in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Variation in age at cancer diagnosis in familial versus nonfamilial Barrett's esophagus.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012
    Trial
  6. Predictive Genetic Testing in the Cancer Management and Prevention.Journal of cancer science and clinical therapeutics · 2025
    Article
  7. Evidenced-Based Screening Strategies for a Positive Family History.Gastrointestinal endoscopy clinics of North America · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Modeling Individual Patient Preferences for Colorectal Cancer Screening Based on Their Tolerance for Complications Risk.Medical decision making : an international journal of the Society for Medical Decision Making · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. How can polygenic inheritance be used in population screening for common diseases?Genetics in medicine : official journal of the American College of Medical Genetics · 2013
    Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Janneke A WilschutDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. j.wilschut@erasmusmc.nl
Ewout W Steyerberg
Monique E van Leerdam
Iris Lansdorp-Vogelaar
J Dik F Habbema
Marjolein van Ballegooijen
Erasmus MC · NLErasmus University Rotterdam · NL

Funding

Modeling Effective Health Policies for Colorectal CancerU01CA097426 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI ZAUBER, ANN GRAHAM · 2002 to 2010
$2.2M
Coordinating Center for Colorectal MicrosimulationU01CA115953 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI ZAUBER, ANN GRAHAM · 2005 to 2009
$1.1M
Targeted Imaging using Adenoviral VectorsR01CA115935 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GERARD, ROBERT D · 2007 to 2010
$1.1M
NCI NIH HHS R01 CA115935NCI NIH HHS U01 CA097426NCI NIH HHS U01 CA115935NCI NIH HHS U01 CA115953NCI NIH HHS U01 CA97426
6 · The paper itself

Abstract

backgroundIndividuals with a family history of colorectal cancer (CRC) are at increased risk for CRC. Current screening recommendations for these individuals are based on expert opinion. The authors investigated optimal screening strategies for individuals with various degrees of family history of CRC based on a cost-effectiveness analysis.

methodsThe MISCAN-Colon microsimulation model was used to estimate costs and effects of CRC screening strategies, varying by the age at which screening was started and stopped and by screening interval. The authors defined 4 risk groups, characterized by the number of affected first-degree relatives and their age at CRC diagnosis. For all risk groups, the optimal screening strategy had an incremental cost-effectiveness ratio of approximately $50,000 per life-year gained.

resultsThe optimal screening strategy for individuals with 1 first-degree relative diagnosed after age 50 years was 6 colonoscopies every 5 years starting at age 50 years, compared with 4 colonoscopies every 7 years starting at age 50 years for average risk individuals. The optimal strategy had 10 colonoscopies every 4 years for individuals with 1 first-degree relative diagnosed before age 50 years, 13 colonoscopies every 3 years for individuals with 2 or more first-degree relatives diagnosed after age 50 years, and 15 colonoscopies every 3 years for individuals with 2 or more first-degree relatives of whom at least 1 was diagnosed before age 50 years.

conclusionsThe optimal screening strategy varies considerably with the number of affected first-degree relatives and their age of diagnosis. Shorter screening intervals than the currently recommended 5 years may be appropriate for the highest risk individuals.

Indexed as

ColonoscopyHealth Planning GuidelinesAge FactorsColorectal NeoplasmsCost-Benefit AnalysisEarly Detection of CancerFamily HealthHumansMiddle AgedRisk FactorsSensitivity and SpecificitySoftware

Identifiers

PMID21387272
PMCPMC3115513
OpenAlexW2069093910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.